YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Cantor Fitzgerald initiated Lexicon Pharmaceuticals (LXRX [https://seekingalpha.com/symbol/LXRX]) at overweight, saying that it is optimistic on upcoming phase 3 data of the SGLT1/2 in…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) and Lexicon Pharmaceuticals reached a key milestone in the development o…
Lexicon Pharmaceuticals, Inc. LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1 billion in total…
The hypertrophic cardiomyopathy market is expected to witness significant growth, driven by increasing disease awareness, improved diagnosis rates, and the emergence of targeted disease-modifying therapies including Sotagliflozin (ZYNQUIST…
This article first appeared on GuruFocus. Total Revenue: $0.7 million for Q2 2026, compared to $28.9 million in Q2 2025. Licensing Revenue: Q2 2025 included $27.5 million in licensing revenue from the Novo Nordisk agreement; no comparable…
Key Points Interested in Lexicon Pharmaceuticals, Inc.? Here are five stocks we like better. Revenue fell sharply to $0.7 million from $28.9 million a year earlier, while Lexicon reported a $31.8 million net loss versus $3.3 million in net…
Lexicon Pharmaceuticals, Inc. Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing b…
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.41 per share a year ago. These figures are adjusted for non-recurring…
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has gained more than 15% over the past month, mainly driven by the stock's inclusion in the Russell 3000 index and strong Q1 2026 earnings. Wall Street expects more than 21% upside over the next…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images The health care sector (XLV [https://seekingalpha.com/symbol/XLV]) had its best week against the S&P 500 (SP500 [http…
Lexicon Pharmaceuticals LXRX is advancing its cardiometabolic franchise, led by its sole marketed drug, sotagliflozin. Sotagliflozin, an oral inhibitor of sodium-glucose cotransporter types I and II (SGLT1 and SGLT2), has been marketed in…
Is LXRX a good stock to buy? We came across a bullish thesis on Lexicon Pharmaceuticals, Inc. on BioEquity Watch's Substack. In this article, we will summarize the bulls' thesis on LXRX. Lexicon Pharmaceuticals, Inc.'s share was trading at…
Key Points Lexicon Pharmaceuticals focuses on precision medicines for chronic conditions, bolstered by significant revenue growth from its core drug programs. Pfizer remains a global giant with immense cash flow and a massive international…
Investors deciding between Lexicon Pharmaceuticals(NASDAQ:LXRX) and Pfizer(NYSE:PFE) face a choice between an emerging high-growth biotech player and an established global pharmaceutical titan with massive scale. These two companies operat…
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 11, 2026, Citi raised the firm’s price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $3.10 from $2.30 and maintained a B…
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy right now. On May 7, Lexicon Pharmaceuticals reported Q1 2026 revenue of $21.1 million, a significant increase from $1.3 million in the prior y…
Lexicon Pharmaceuticals, Inc. $55 million funded at closing to repay existing loan facility THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Novo Nordisk (NYSE:NVO) is exploring semaglutide as a potential tre…
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best biotech penny stocks to buy in 2026. On March 23, Lexicon Pharmaceuticals and Novo Nordisk (NYSE:NVO) initiated a Phase 1 clinical study for LX9851, a first-in-class, oral non-…
THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to market open. Managem…
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 16, 2026, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that results from its PROGRESS Phase 2b study of pilavapadin…
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further validates the broader potential importance…
Shares of Lexicon Pharmaceuticals LXRX gained 5.1% on Monday after the company announced that its partner, Novo Nordisk NVO, a dominant player in the obesity market, has initiated an early-stage study of LX9851, a first-in-class, oral non-…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Novo Nordisk (CPSE:NOVO B) has kicked off a Phase 1 trial of LX9851…
The study is investigating the safety and tolerability of LX9851, how it moves through the body and its physiological and biological impacts. Continue Reading
Lexicon Pharmaceuticals, Inc. LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential $10 millio…
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the High-Flying Penny Stocks to Buy. On March 12, H.C. Wainwright reiterated a Buy rating on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) with a $6 price target. The analyst noted posit…
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is among the 11 Fastest Growing Penny Stocks to Buy Right Now.H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy Rating On March 5,…
Shares of Xenon Pharmaceuticals XENE surged 49.6% yesterday after the company announced positive top-line data from the phase III X-TOLE2 study, which evaluated its lead pipeline candidate, azetukalner for treating focal onset seizures (FO…
Lexicon Pharmaceuticals, Inc. Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and…
The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment…
THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock,…
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy according to analysts. On January 14, Citi analyst Yigal Nochomovitz increased the price target for Lexicon to $2.10 from $1.90 while maintainin…
THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock,…
THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other condition…
Apellis Pharmaceuticals, Inc. (APLS) shares ended the last trading session 5.8% higher at $23.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's…